<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2609">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332107</url>
  </required_header>
  <id_info>
    <org_study_id>20-30504</org_study_id>
    <nct_id>NCT04332107</nct_id>
  </id_info>
  <brief_title>Azithromycin for COVID-19 Treatment in Outpatients Nationwide</brief_title>
  <acronym>ACTION</acronym>
  <official_title>Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas M. Lietman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This individually randomized telemedicine-based trial aims to evaluate the efficacy of a&#xD;
      single dose of azithromycin for prevention of progression of COVID-19 in patients with a&#xD;
      recent positive SARS-CoV-2 test who are not currently hospitalized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identification of a safe, effective treatment for individuals with mild or moderate COVID-19&#xD;
      that prevents disease progression and reduces hospitalization would reduce the burden on the&#xD;
      health system. High dose hydroxychloroquine is being evaluated for SARS-CoV-2 prevention and&#xD;
      COVID-19 disease treatment, but has a high risk of a number of potentially severe adverse&#xD;
      events. Recent evidence has indicated that the broad-spectrum macrolide azithromycin may have&#xD;
      some activity against coronaviruses. Here we propose an individually-randomized,&#xD;
      placebo-controlled trial to determine the efficacy of a single dose of azithromycin for&#xD;
      prevention of COVID-19.&#xD;
&#xD;
      Potential participants will undergo remote eligibility screening with study staff prior to&#xD;
      enrollment. Upon determination of eligibility and signing electronic informed consent&#xD;
      documents, participants will be emailed baseline study forms and will be mailed their&#xD;
      randomized study treatment. At the end of the study (21 days), participants will be emailed a&#xD;
      final study questionnaire. Note that there will no contact between study staff and&#xD;
      participants in this trial, minimizing risk of infection spread.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 14 Binary Assessment of Symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Binary assessment of whether the participant is experiencing any symptoms at Day 14 (yes or no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>3 days</time_frame>
    <description>Viral load by self-collected nasal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>3 days</time_frame>
    <description>Viral load by self-collected saliva swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>14 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 days</time_frame>
    <description>Proportion of participants experiencing adverse events, including gastrointestinal side effects and rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 test - nasal swab</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of positive SARS-CoV-2 test by self-collected nasal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 test - saliva swab</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of positive SARS-CoV-2 test by self-collected saliva swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 test - rectal swab</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of positive SARS-CoV-2 test by self-collected rectal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic macrolide resistance determinants</measure>
    <time_frame>3 days</time_frame>
    <description>Prevalence of genetic macrolide resistance determinants by self-collected rectal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 symptoms</measure>
    <time_frame>3, 7, 14, 21 days</time_frame>
    <description>Prevalence of cough, fever, myalgia, anosmia, shortness of breath, fatigue, conjunctivitis, and orthostatic symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency room visits</measure>
    <time_frame>14 days</time_frame>
    <description>Number of emergency room visits &lt;24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of household members with COVID-19 (confirmed or symptomatic)</measure>
    <time_frame>14 days</time_frame>
    <description>Number of household members with confirmed or symptomatic COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>21 days</time_frame>
    <description>Deaths within the study will be attempted to be matched with the US National Death Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>14 Days</time_frame>
    <description>Number of hospitalizations defined as a hospital stay or ER stay longer than 24 hours at 14 days post enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2271</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2g of oral azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Participants will be shipped a single 1.2 g dose of oral azithromycin</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Participants will be shipped a dose of matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of a positive SARS-CoV-2 test and test results received within the previous&#xD;
             seven days&#xD;
&#xD;
          -  Not currently hospitalized&#xD;
&#xD;
          -  Willing and able to receive study drug by mail&#xD;
&#xD;
          -  Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via&#xD;
             email or over the phone&#xD;
&#xD;
          -  No known allergy or other contraindication to macrolides&#xD;
&#xD;
          -  Age 18 years or older at the time of enrollment&#xD;
&#xD;
          -  No known history of prolongation of the QT interval (eg. History of torsades de&#xD;
             pointes, congenital long QT syndrome, bradyarrhthmia)&#xD;
&#xD;
          -  No recent use of hydroxychloroquine within the past 7 days for participants &gt;55 years&#xD;
             of age&#xD;
&#xD;
          -  Not currently taking nelfinavir or warfarin (Coumadin)&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
          -  Not currently pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Oldenburg, ScD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thuy Doan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica M Brogdon, MPH</last_name>
    <phone>(415) 514-1582</phone>
    <email>ACTIONTrial@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Cook, MPH</last_name>
    <email>ACTIONTrial@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica M Brogdon, MPH</last_name>
      <phone>415-514-1582</phone>
      <email>ACTIONTrial@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

